ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Z 338

Also written as “Z-338”, “YM443” and “Acotiamide hydrochloride hydrate”.

Its studies are mostly in Dyspepsia, led by 3 companies.

Drug pageZ 338: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 25, 200812 company-led studies, 1 open or runningNext primary completion: Dec 30, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Zeria Pharmaceutical70 open or runningphase 3since Sep 25, 2008Feb 28, 2006none ahead
Astellas Pharmaits history only40 open or runningphase 3since Sep 30, 2008Jan 26, 2005none ahead
Getz Pharmaits history only11 open or runningphase 3since Sep 12, 2025Sep 12, 2025Dec 30, 2026phase 3 · NCT07174297

Also a collaborator on its studies: Astellas Pharma US.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Zeria Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 28, 2006First study: phase 2 study in DyspepsiaFirst studyNCT00298194 · 52 enrolled · Australia
  2. May 8, 2006Phase 2 study in Functional DyspepsiaNCT00323817 · 282 enrolled · Belgium
  3. Jun 2, 2006Phase 2 study in Functional DyspepsiaNCT00333372 · 440 enrolled · Japan
  4. Apr 9, 2007Phase 2 study in Functioanl DyspepsiaNCT00458328 · 40 enrolled · Japan
  5. Sep 25, 2008Phase 3 study in Functional DyspepsiaNCT00761358 · 820 enrolled · Japan
  6. Oct 26, 2013Phase 3 study in DyspepsiaNCT01973790 · 207 enrolled · Belgium, Bulgaria, Latvia and more
  7. Aug 19, 2020Phase 3 study in Functional DyspepsiaNCT04526119 · 55 enrolled · Japan

TargetBeta

ACHE →read by rule
“Acetylcholinesterase inhibitor”ChEMBL 37, by rule

Other programs on ACHE

ProgramCompanyFurthest phaseStudies
DonepezilruleEisaiphase 483
huperzine Arulewanbangde-pharmaceutical-group-co-ltdphase 47
benzgalantamine gluconaterulealpha-cognition-incphase 41

Studies

All 7 Zeria Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04526119Functional Dyspepsia · Japan3CompletedMar 2, 202655
NCT01973790Dyspepsia · Belgium, Bulgaria, Latvia and more3CompletedNov 2016207
NCT00761358Functional Dyspepsia · Japan3CompletedJun 2010820
NCT00458328Functioanl Dyspepsia · Japan2CompletedSep 200940
NCT00333372Functional Dyspepsia · Japan2Completed440
NCT00323817Functional Dyspepsia · Belgium2CompletedApr 2009282
NCT00298194Dyspepsia · Australia2CompletedJul 200852

How it is read

Names in the registry

  • “Z-338”, 7 entries
  • “YM443”, 3 entries
  • “Acotiamide hydrochloride hydrate”, 1 entry
  • “Acotiamide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.